A USC research team discovered that a single genetic signal may be preventing both hearing and vision cells from repairing themselves. By turning off this signal in mice, they triggered cell growth in ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approv ...

Explore daily insights on the USA TODAY crossword puzzle by Sally Hoelscher. Uncover expert takes and answers in our ...

Transgenic worm in which the splicing factor UNC-75, marked with the fluorophore mScarlet, reveals its expression throughout the nervous system. The worm was generated using CRISPR-Cas9 gene editing ...

The results of this work reveal how an alternative splicing mechanism regulates an essential factor for neuronal identity.

Alternative RNA splicing is like a movie editor cutting and rearranging ... Similarly, cells splice RNA in different ways to produce a variety of proteins from a single gene, fine-tuning their ...

Breakthrough discovery in cancer research! Scientists uncover a simple genetic strategy to combat aggressive cancers. Learn how this innovative approach could revolutionise cancer treatment and save ...

Please check this box if you wish to receive updates and information about the upcoming IMAGE PwC Businesswoman of the Year Awards 2025 by being added to our mailing list. By clicking subscribe, you ...

An RNA-Seq data exploration tool that shows read map coverage of a gene of interest along with a coloured "electronic fluorescent pictographic" (eFP) based on its RPKM expression level.

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

By Gina Kolata Researchers have corrected a disease-causing gene mutation with a single infusion carrying a treatment that precisely targeted the errant gene. This was the first time a mutated ...